Physician profile
Fadi E Rahhal
NPI 1306062724
$8,366.33
in general payments reported to CMS, 2019-2025
29 companies · $1,643 in 2025
The $1,643 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $477 · 2021: $1,020 · 2022: $1,409 · 2023: $1,355 · 2024: $2,002 · 2025: $1,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,000.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,543.97 | 2019-2025 | |
| Pfizer INC. | $970.88 | 2019-2025 | |
| Axonics, INC. | $564.66 | 2022-2024 | Axonics |
| Phathom Pharmaceuticals, INC. | $508.70 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $322.65 | 2019-2025 | Entyvio |
| Genzyme Corporation | $291.77 | 2023-2025 | |
| Janssen Biotech, INC. | $222.03 | 2021-2025 | Stelara, Simponi Aria, Simponi |
| Boston Scientific Corporation | $207.88 | 2025 | Axonics |
| Madrigal Pharmaceuticals | $191.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $172.73 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $163.87 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.48 | 2020-2023 | Trulance |
| Regeneron Healthcare Solutions, INC. | $149.05 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $95.98 | 2021-2023 | Rebyota |
| Vivus LLC | $94.25 | 2019-2024 | Pancreaze |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $90.73 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $81.71 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $79.93 | 2021-2022 | |
| Ardelyx, INC. | $79.76 | 2023-2024 | Ibsrela |
| Organon LLC | $71.23 | 2023-2024 | Hadlima |
| Redhill Biopharma INC. | $69.07 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $56.74 | 2021-2022 | |
| Allergan, INC. | $54.43 | 2019 | |
| Braintree Laboratories, INC. | $43.89 | 2022-2023 | Suflave |
| Phadia US INC. | $21.96 | 2023 | Immunocap |
| Lilly USA, LLC | $20.34 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $16.24 | 2023 | Ocaliva |
| Daiichi Sankyo INC. | $15.07 | 2021 | |
| Evoke Pharma, INC. | $12.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Rahhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.